These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38234941)
1. Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-M Alloantibody in Myelofibrosis: A Case Report. Alsoreeky MS; Lutfi LK; Altamimi AA; Haddad TH; Khalayleh MS; Alkader MS Cureus; 2023 Dec; 15(12):e50717. PubMed ID: 38234941 [TBL] [Abstract][Full Text] [Related]
2. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582 [TBL] [Abstract][Full Text] [Related]
3. Anti-N and anti-Do Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787 [TBL] [Abstract][Full Text] [Related]
4. An Unusual Case of Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-Jk El Alaoui K; Benghiat FS; Colard M J Hematol; 2022 Apr; 11(2):66-70. PubMed ID: 35573755 [TBL] [Abstract][Full Text] [Related]
5. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194 [TBL] [Abstract][Full Text] [Related]
6. Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab. Fuja C; Kothary V; Carll TC; Singh S; Mansfield P; Wool GD Transfusion; 2022 Jul; 62(7):1446-1451. PubMed ID: 35588309 [TBL] [Abstract][Full Text] [Related]
7. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature. Menakuru SR; Priscu A; Dhillon V; Salih A Hematol Rep; 2022 Jul; 14(3):235-239. PubMed ID: 35893156 [TBL] [Abstract][Full Text] [Related]
9. Can we better predict delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease? Adkins BD; Sharma D; Eichbaum Q Transfus Apher Sci; 2020 Apr; 59(2):102681. PubMed ID: 31831326 [TBL] [Abstract][Full Text] [Related]
10. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Chadebech P; Habibi A; Nzouakou R; Bachir D; Meunier-Costes N; Bonin P; Rodet M; Chami B; Galacteros F; Bierling P; Noizat-Pirenne F Transfusion; 2009 Sep; 49(9):1785-92. PubMed ID: 19413729 [TBL] [Abstract][Full Text] [Related]
11. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome. Lukin R; Law JY; Lokhandwala PM Transfus Apher Sci; 2024 Jun; 63(3):103919. PubMed ID: 38582651 [TBL] [Abstract][Full Text] [Related]
12. Hyperhemolysis syndrome in anemia of chronic disease. Darabi K; Dzik S Transfusion; 2005 Dec; 45(12):1930-3. PubMed ID: 16371046 [TBL] [Abstract][Full Text] [Related]
13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab. Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065 [TBL] [Abstract][Full Text] [Related]
14. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment. Hannema SE; Brand A; van Meurs A; Smiers FJ Transfusion; 2010 Feb; 50(2):429-32. PubMed ID: 19788508 [TBL] [Abstract][Full Text] [Related]
15. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Balbuena-Merle R; Hendrickson JE Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806 [TBL] [Abstract][Full Text] [Related]
16. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228 [TBL] [Abstract][Full Text] [Related]
17. Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: A Case Series. Alwaheed AJ; Alqatari SG; AlSulaiman AS; AlSulaiman RS Am J Case Rep; 2022 Jan; 23():e934681. PubMed ID: 34983921 [TBL] [Abstract][Full Text] [Related]